MedTrace Logo

MyoStrain CMR for the Detection of Cardiotoxicity

NCT03543228 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2021-06-25

No results posted yet for this study

Summary

The Prefect Pilot Study evaluates the use of the EC approved MyoStrain SENC CMR Imaging System to detect cardiotoxicity from drugs used to treat cancer (e.g. Breast Cancer and Lymphomas).

Conditions

Interventions

DIAGNOSTIC_TEST

MyoStrain

MyoStrain quantifies myocardial contraction to detect changes in heart function during chemotherapy.

Sponsors & Collaborators

  • Myocardial Solutions

    lead INDUSTRY

Principal Investigators

  • Henning Steen, MD · Marien Krankenhaus

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2020-01-31
Completion
2020-01-31
FDA Device
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03543228 on ClinicalTrials.gov